Neuroblastoma Market Research Report – Forecast to 2027

Global Neuroblastoma Research Report: Information by Diagnostics (MIBG Scan and Biopsy), by Treatment (Surgical), and by End User (Hospitals and Others)—Forecast till 2027

ID: MRFR/Pharma/5093-HCR | February 2021 | Region: Global | 90 pages         

Global Neuroblastoma Market

Neuroblastoma market is expected to grow steadily USD 2.2 billion by 2027, at CAGR 9.1% over the forecast period

Segmentation

By Diagnostics MIBG Scan and Biopsy
By Treatment Surgical
By End User Hospitals and Others

Key Players

  • Corp.
  • APEIRON Biologics AG
  • LUMITOS AG
  • NANTGE Healthcare
  • Pfizer Inc.
  • GL Pharm Tech Corporation
  • Aetna Inc
  • RxStrategies
  • Inc.

Drivers

  • increasing case of childhood cancer
Speak to Analyst Request a Free Sample

Neuroblastoma Market Scenario


The neuroblastoma market is expected to grow steadily over the forecast period. It is projected that the market held a market value of USD 2.60 billion in 2016 and is projected to grow at a CAGR of 3.7% over the forecast period. Neuroblastoma is a common cancer detected in infants. Neuroblastoma develops from immature nerve cells found in various parts of the body. It most commonly occurs in children or young ones below 5 years old. The patient having neuroblastoma may cause symptoms such as backbone pain, weight loss, abdominal pain, enlarged stomach, bulging eyes, weight, crankiness, anemia, fever, bone pain, dark circles around the eyes, weakness, high blood pressure, and constipation or diarrhea. 


The factors such as a mutation in germline cells, change in lifestyle and family history of neuroblastoma may cause this disease. In some cases, it may cause due to the use of fertility drugs, maternal use of hair dye, infection, and, atopy. According to the American Childhood Cancer Organization and the International Agency for Research on Cancer (IARC) 2016 report release, it was estimated that approximately 80,000 deaths are caused by childhood cancer globally. Such an increasing case of childhood cancer every year may support this market positively. However, due to the late effects associated with neuroblastoma treatment such as loss of some organ function or hearing loss and others may restrain the neuroblastoma market growth. Also, the high cost of this therapy over the conventional treatment or side effects associated with the treatment can hamper the market growth. Also, the dearth of skilled healthcare professionals can hamper the market growth over the forecast period.


Segmentation


The neuroblastoma market has been segmented into diagnostics, treatment, and end user.


The market, on the basis of diagnostics, has been segmented into various tests, MIBG scan, imaging, and biopsy. The tests are further sub-segmented into bone marrow, tissue, urine, and blood.


The market, by treatment, has been segmented into surgery, chemotherapy, radiation therapy, stem cell transplant, immunotherapy, and monoclonal antibody treatment. The market, by end user, has been segmented into hospitals ambulatory surgical centers, diagnostic centers, research centers, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The neuroblastoma market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European neuroblastoma market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.


The neuroblastoma market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The neuroblastoma market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


United Therapeutics Corp., APEIRON Biologics AG, LUMITOS AG, NANTGE Healthcare, Pfizer Inc., GL Pharm Tech Corporation, Aetna Inc, RxStrategies, Inc., and others are some of the key players in the global neuroblastoma market.


Regional Market Summary


Global Neuroblastoma Market Share (%), by Region, 2017


Neuroblastoma Market Share


Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports


Geographically, the Americas is predicted to dominate the global neuroblastoma market owing to a well-developed healthcare sector and growing incidences of childhood cancer. According to the American Society of Clinical Oncology (ASCO) in April 2018, article neuroblastoma accounts for 6% of all childhood cancers in the US. It was also indicated that it is the third most common type of cancer in infants. This influences the market growth in North America.


Europe is likely to hold the second largest position in the global neuroblastoma market. The market growth in this region is attributed to the increasing number of infant’s cancer with developed healthcare infrastructure.  According to the Cancer Research UK May 2016, statistics 1,821 new cases of children's cancer was listed in 2013-2015, in the UK. The increase in cases of childhood cancer in this region supports this market growth.


The neuroblastoma market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is predictable to be the fastest growing region due to the enormous patient population of childhood cancer and increasing development of hospitals for childhood cancer treatment in the Asia-Pacific region.


The Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.


Global Neuroblastoma Market, by Diagnostics



  • Tests

  • Bone Marrow Testing

  • Tissue Testing

  • Urine and Blood Testing

  • MIBG Scan

  • Imaging

  • Biopsy


Global Neuroblastoma Market, by Treatment



  • Medications

  • Surgery

  • Chemotherapy

  • Radiation therapy

  • Stem Cell Transplant

  • Immunotherapy

  • Monoclonal antibody treatment


Global Neuroblastoma Market, by End User



  • Hospitals and clinics

  • Ambulatory Surgical Centers

  • Diagnostic Centers

  • Research centers

  • Others


Global Neuroblastoma Market, by Region


Americas



  • North America

  • US

  • Canada

  • South America


Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe


Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific


Middle East & Africa



  • Middle East

  • Africa


Global Neuroblastoma Market, by Key Players


United Therapeutics Corp., APEIRON Biologics AG, LUMITOS AG, NANTGE Healthcare, Pfizer Inc., GL Pharm Tech Corporation, Aetna Inc, RxStrategies, Inc., and others are some of the key players in the global neuroblastoma market.


Intended Audience



  • Manufacturers and vendors

  • Research associations related to  cancer in children

  • Hospitals and clinics

  • Various research and consulting firms



Report Scope:
Report Attribute/Metric Details
  Market Size   2017 : USD 2.60 Billion
  CAGR   3.7% (2018 - 2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units    Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Diagnostics, Treatment, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   United Therapeutics Corp., APEIRON Biologics AG, LUMITOS AG, NANTGE Healthcare, Pfizer Inc., GL Pharm Tech Corporation, Aetna Inc, RxStrategies, Inc
  Key Market Opportunities   Joint ventures, strategic alliances, mergers and acquisitions and new product developments
  Key Market Drivers   Rising prevalence of childhood cancer


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The neuroblastoma market is projected to grow at a 3.7% CAGR between 2020-2027.

The Americas is projected to command the largest share in the neuroblastoma market.

Key players profiled in the neuroblastoma market include RxStrategies, Inc., Aetna Inc, GL Pharm Tech Corporation, Pfizer Inc., NANTGE Healthcare, LUMITOS AG, APEIRON Biologics AG, and United Therapeutics Corp.

Rising prevalence of childhood cancer is boosting market growth.

High therapy cost and shortage of specialists may limit market growth.